You are in: eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > NASAL AND SINUS DISEASES Sinusitis, Chronic, Medical TreatmentArticle Last Updated: Aug 4, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Seth M Brown, MD, MBA, Clinical Faculty, University of Connecticut School of Medicine Seth M Brown is a member of the following medical societies: American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Rhinologic Society, and North American Skull Base Society Coauthor(s): Marvin Peter Fried, MD, University Chairman, Department of Otorhinolaryngology, Montefiore Medical Center, Albert Einstein College of Medicine; Babak Sadoughi, MD, House Officer, Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center; Osama A Abdel Razek, MBBCh, MSc, Research Fellow, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard University Medical School; Dennis Poe, MD, Clinical Assistant Professor, Departments of Otology and Laryngology, Harvard University Medical Center, Boston University School of Medicine Editors: Lanny Garth Close, MD, Chair, Professor, Department of Otolaryngology-Head and Neck Surgery, Columbia University College of Physicians and Surgeons; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Stephen G Batuello, MD, Consulting Staff, Colorado ENT Specialists; Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders; Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine Author and Editor Disclosure Synonyms and related keywords: chronic sinusitis, chronic rhinosinusitis, recurrent sinusitis, chronic rhinitis, recurrent rhinitis, runny nose, sinus congestion, chronic congestion, chronic sinus congestion, recurrent sinus congestion, chronic cold, recurrent cold, orbital infection, orbit infection, sinus pain, sinus pressure, postnasal discharge, sinus obstruction, purulent rhinorrhea, rhinorrhea, post-nasal drip, postnasal drip, maxillary sinusitis, ethmoid sinusitis, frontal sinusitis, anaerobic cocci infection, bacteroid infection, streptococcal infection, Staphylococcus aureus, Bacteroides, Streptococcus, S aureus, Staphylococcus INTRODUCTIONBackgroundChronic sinusitis is an inflammatory process that involves the paranasal sinuses and persists for 12 weeks or longer. Recently, literature has supported that chronic sinusitis is almost always accompanied by concurrent nasal airway inflammation and is often preceded by rhinitis symptoms; thus, the term chronic rhinosinusitis (CRS) has evolved to more accurately describe this condition. A recent multidisciplinary consensus statement on CRS supported that the definition of CRS requires 2 or more of the following symptoms: anterior or posterior mucopurulent drainage, nasal obstruction, or facial-pain-pressure-fullness. The definition of CRS also requires both endoscopy, to document the presence of inflammation, and evidence of rhinosinusitis on imaging. PathophysiologyThe pathophysiology of this disorder is poorly defined. Current thinking supports that CRS is predominantly an inflammatory disease. Confounding factors that may contribute to inflammation include the following:
All of these factors can play a role in disruption of the intrinsic mucociliary transport system. This is because an alteration in sinus ostia patency, ciliary function, or the quality of secretions leads to stagnation of secretions, decreased pH levels, and lowered oxygen tension within the sinus. These changes create a favorable environment for bacterial growth that, in turn, further contribute to increased mucosal inflammation. FrequencyUnited StatesThe overall prevalence of CRS in the United States is 146 per 1000 population. This involves nearly 30 million US adults yearly, making CRS more common than any other chronic condition. For unknown reasons, the incidence of this disease appears to be increasing yearly. This results in a conservative estimate of 18-22 million physician visits in the United States each year and a direct treatment cost of $3.4-5 billion annually. Mortality/MorbiditySinusitis is rarely life-threatening, although serious complications can occur because of the proximity to the orbit and cranial cavity.
AgeRhinosinusitis is more common in the pediatric population because this term includes both acute and chronic infection and both viral and bacterial disease. This is likely secondary to an increased frequency of exposure to upper respiratory tract infections in the pediatric population. CLINICALHistoryPatient history is extremely important in CRS because of the broad overlap between sinus symptoms and other disease processes, as well as poor correlation between symptoms and endoscopic and radiographic findings. Consequently, a number of key factors in the patient's history should be discerned. They are as follows:
PhysicalThe physical examination should include a complete head and neck examination to confirm the diagnosis and to rule out more serious disorders.
CausesA number of factors often contribute to the inflammatory process that causes CRS. Please see Pathophysiology for a discussion on etiology.
DIFFERENTIALSAllergic Fungal Sinusitis Allergic Rhinitis Cystic Fibrosis Foreign Bodies of the Airway Juvenile Nasopharyngeal Angiofibroma Malignant Nasopharyngeal Tumors Malignant Tumors of the Nasal Cavity Malignant Tumors of the Sinuses Nonallergic Rhinitis Sinusitis, Fungal Skull Base, Benign Tumors Turbinate Dysfunction
|
| Drug Name | Amoxicillin clavulanate (Augmentin) |
|---|---|
| Description | Extends the antibiotic spectrum of penicillin to include bacteria normally resistant to beta-lactam antibiotics; available in tabs, chewables, and susp. A newer extended-release product is available as amoxicillin 1000 mg and clavulanate 62.5 mg. |
| Adult Dose | 875 mg PO bid 10 d minimum for regular product |
| Pediatric Dose | 45 mg/kg/d PO divided bid or 40 mg/kg/d divided tid 10 d minimum |
| Contraindications | Documented hypersensitivity to Augmentin or penicillin. |
| Interactions | Risk of bleeding increases when coadministered with warfarin or heparin, possibly because of additive effects |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Perform bacteriologic studies to determine causative organisms and susceptibility so that appropriate therapy is administered; use therapy for 3-4 wk in cases of real chronic sinusitis |
| Drug Name | Cefuroxime (Ceftin) |
|---|---|
| Description | Second-generation cephalosporin maintains gram-positive activity that first-generation cephalosporins have; adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and M catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration. |
| Adult Dose | 250-500 mg PO bid 10 d minimum |
| Pediatric Dose | Suspension: 20-30 mg/kg/d PO bid 10 d minimum |
| Contraindications | Documented hypersensitivity to product |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h of administration; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patient receiving potent diuretics (eg, loop diuretics); coadministration with aminoglycosides increases nephrotoxic potential |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Administer half dose if CrCl 10-30 mL/min and quarter dose if <10 mL/min; fungal and microorganism overgrowth may occur with prolonged therapy |
| Drug Name | Clarithromycin (Biaxin) |
|---|---|
| Description | Reversibly binds to P site of 50S ribosomal subunit of susceptible organisms; may inhibit RNA-dependent protein synthesis by stimulating dissociation of peptidyl t-RNA from ribosomes. |
| Adult Dose | 250-500 mg PO bid 10 d minimum |
| Pediatric Dose | 15 mg/kg/d PO divided bid 10 d minimum |
| Contraindications | Documented hypersensitivity; patients taking pimozide |
| Interactions | Coadministration with fluconazole may significantly increase levels; similarly, coadministration with pimozide may result in toxic levels and possibly death; conversely, antimicrobial effects may be decreased when taken concurrently with rifabutin or rifampin, while the frequency of adverse GI effects may be increased Monitor anticoagulant function in patients receiving anticoagulants concurrently with any macrolide antibiotic Adverse cardiovascular effects (eg, torsade de pointes, other ventricular effects) leading to cardiac arrest and reportedly death may occur when taken concurrently with astemizole Plasma levels of certain benzodiazepines may increase, prolonging CNS depressant effects; carbamazepine concentrations may increase when taken concurrently Serum digoxin concentrations may increase as a result of effects of antibiotic on gut flora that metabolize digoxin in more than 10% of patients; disopyramide plasma levels may increase when taken concurrently, causing arrhythmias and increasing QT intervals Monitor patients receiving ergot alkaloids and any macrolide antibiotic; acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia may occur when taken concurrently Risk of severe myopathy or rhabdomyolysis associated with HMG-CoA reductase inhibitors may be increased when taken concurrently Coadministration with omeprazole may increase plasma levels of both drugs Concurrent use of tacrolimus may be associated with elevated serum tacrolimus levels, increasing the risk of adverse effects (eg, nephrotoxicity) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Clarithromycin in combination with ranitidine bismuth citrate therapy is not recommended in patients with CrCl <25 mL/min; patients with severe renal impairment (CrCl <30 mL/min) with or without coexisting hepatic impairment should receive half dose, but dosing interval may be doubled under these circumstances; consider the possibility of pseudomembranous colitis in patients who present with diarrhea subsequent to the administration of clarithromycin; risk of secondary infections present with prolonged or repeated antimicrobial therapy because it may result in bacterial or fungal overgrowth of nonsusceptible organisms; appropriate measures should be taken if superinfection occurs |
| Drug Name | Azithromycin (Zithromax) |
|---|---|
| Description | Advanced-generation macrolide; works similarly to clarithromycin but with shorter dosage time. |
| Adult Dose | 500 mg PO initially, then 250 mg PO for 4 d |
| Pediatric Dose | <16 years: Not established; suggested dose is 10 mg/kg initially, followed by 5 mg/kg PO for 4 d |
| Contraindications | Documented hypersensitivity; patients taking pimozide |
| Interactions | May increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Site reactions can occur with IV route; bacterial or fungal overgrowth may result with prolonged antibiotic use; may increase hepatic enzyme levels and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in hospitalized, geriatric, or debilitated patients |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at the bacterial ribosome, where it preferentially binds to the 50S ribosomal subunit, thus causing inhibition of bacterial growth. |
| Adult Dose | 150-450 mg PO qid with a full glass of water 10 d minimum |
| Pediatric Dose | Children 8-20 mg/kg/d PO divided tid/qid; dosage administered depends on severity of infection; oral dosage (clindamycin palmitate hydrochloride oral granules) |
| Contraindications | Documented hypersensitivity, regional enteritis, ulcerative colitis, hepatic impairment, antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Dose adjustment may be necessary in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; use has been associated with severe and possibly fatal colitis |
| Drug Name | Cefaclor (Ceclor) |
|---|---|
| Description | Indicated for management of infections caused by susceptible mixed aerobic-anaerobic microorganisms. |
| Adult Dose | 250-500 mg PO tid 10 d minimum |
| Pediatric Dose | 20-40 mg/kg/d PO divided tid 10 d minimum |
| Contraindications | Documented hypersensitivity |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h of administration; may increase hypoprothrombinemic effects of anticoagulants; coadministration with potent diuretics and aminoglycosides (eg, loop diuretics) may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Give half dose if CrCl 10-30 mL/min and quarter dose if <10 mL/min; bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy |
| Drug Name | Cefpodoxime (Vantin) |
|---|---|
| Description | Indicated for management of infections caused by susceptible mixed aerobic-anaerobic microorganisms. |
| Adult Dose | 100-400 mg PO bid |
| Pediatric Dose | 10/mg/kg PO divided bid |
| Contraindications | Documented hypersensitivity |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h of administration; may increase hypoprothrombinemic effects of anticoagulants; coadministration with potent diuretics and aminoglycosides (eg, loop diuretics) may increase nephrotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Give half dose if CrCl 10-30 mL/min and quarter dose if <10 mL/min; bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy |
| Drug Name | Cefprozil (Cefzil) |
|---|---|
| Description | Binds to one or more of the penicillin-binding proteins, which, in turn, inhibits cell wall synthesis and results in bactericidal activity. |
| Adult Dose | 250-500 mg PO qd or divided bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid increases effect; coadministration with furosemide and aminoglycosides increases nephrotoxic effects |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dosage in renal impairment |
Goals include reduction of tissue edema, facilitation of drainage, and maintenance of patency of sinus ostia. In short, decongestants are necessary to meet the management goals for sinusitis. Decongestants are available in 2 forms, topical and oral. Each agent differs slightly in its method of action.
Topical agents are locally active vasoconstrictor agents such as phenylephrine HCl 0.5% and oxymetazoline HCl 0.5% that provide almost immediate symptomatic relief by shrinking the inflamed and swollen nasal mucosa. Topical nasal formulations should not be used for longer than 3-5 consecutive days because of the risk of development of tolerance, rhinitis medicamentosa, and rebound after drug withdrawal.
Oral systemic agents are used when decongestion is necessary for longer than 3 days. An oral systemic agent, such as phenylpropanolamine (recalled from US market) or pseudoephedrine, is preferred. Oral decongestants are alpha-adrenergic agonists that reduce nasal blood flow. Theoretically, these oral systemic agents have the potential to act on tissues deep in the ostiomeatal complex, where topical agents may not penetrate effectively.
| Drug Name | Pseudoephedrine (Sudafed) |
|---|---|
| Description | Stimulates vasoconstriction by directly activating the alpha-adrenergic receptors of the respiratory mucosa; induces bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors; available in tabs, chewables, solution, extended-release tabs, and infant drops. |
| Adult Dose | 60 mg PO q4-6h; 120-mg SR q12h; not to exceed 240 mg/d |
| Pediatric Dose | 3-12 months: 3 gtt/kg PO q4-6h; not to exceed 4 doses/d 1-2 years: 7 gtt (0.2 mL)/kg PO q4-6h; not to exceed 4 doses/d 2-5 years: 15 mg PO q4-6h; not to exceed 60 mg/d >5 years: 30 mg PO q4-6h; not to exceed 120 mg/d |
| Contraindications | Documented hypersensitivity; methyldopa and reserpine may reduce effects; coadministration with MAOIs may increase blood pressure |
| Interactions | Propranolol, MAOIs and sympathomimetic agents may increase toxicity; methyldopa and reserpine may reduce effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Exercise caution in cardiovascular disease, diabetes mellitus, prostatic hypertrophy, and increased intraocular pressure |
| Drug Name | Oxymetazoline HCl 0.5% (Afrin) |
|---|---|
| Description | Stimulates vasoconstriction by directly activating alpha-adrenergic receptors of the respiratory mucosa. Also induces bronchial relaxation and increases heart rate and contractility by stimulating beta-adrenergic receptors. Provides almost immediate symptomatic relief by shrinking inflamed and swollen nasal mucosa. |
| Adult Dose | 2-3 sprays or 2-3 gtt each nostril bid |
| Pediatric Dose | <6 years: 2-3 gtt of 0.025% solution each nostril bid >6 years: Administer as in adults |
| Contraindications | Documented hypersensitivity, MAOI therapy |
| Interactions | Hypotensive action of guanethidine may be reversed; coadministration with methyldopa may increase vasopressor response; concurrent use of MAOIs and ephedrine may result in hypertensive crisis; pressor sensitivity to mixed-acting agents (eg, ephedrine) may be increased; guanethidine potentiates effects of epinephrine and inhibits effects of ephedrine; phenothiazines may reverse action of nasal decongestants (eg, oxymetazoline); TCAs potentiate vasopressor response and may result in dysrhythmias |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Exercise caution in patients with hyperthyroidism, coronary artery and ischemic heart disease, diabetes mellitus, increased intraocular pressure, or prostatic hypertrophy; because of increase in vasoconstriction, hypertensive patients may experience a change in blood pressure; do not use topical decongestants for longer than 3-5 d |
| Drug Name | Phenylephrine HCl (Neo-Synephrine) |
|---|---|
| Description | Synthetic sympathomimetic amine. |
| Adult Dose | Apply 2-3 gtt or sprays of 0.25-0.5% solution each nostril or small quantity of 0.5% nasal jelly applied into each nostril q4h prn; 1% solution may be used in adults with severe congestion |
| Pediatric Dose | Infants > 6 months: 1-2 gtt 0.125% solution each nostril q4h <6 years: 2-3 gtt or puffs 0.125% solution each nostril q4h prn 6-12 years: 2-3 gtt 0.25% solution each nostril q4h prn |
| Contraindications | Documented hypersensitivity, severe hypertension, ventricular tachycardia |
| Interactions | Bretylium may potentiate action of vasopressors on adrenergic receptors, possibly resulting in arrhythmias; MAOIs may significantly enhance adrenergic effects, and its pressor response may be increased 2-3 times; guanethidine may increase pressor response of direct-acting vasopressors, possibly resulting in severe hypertension |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in elderly patients and those with hyperthyroidism, myocardial disease, bradycardia, partial heart block, or severe arteriosclerosis |
Sinusitis, Chronic, Medical Treatment excerpt
Article Last Updated: Aug 4, 2006